RxDoctor Payments Data

Ashwini Gandhe, MD

Internal Medicine · Aliquippa, PANPI 1447278395

Payments from drug & device makers

$11,956in general payments, 2019–2025

Across 728 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • GSK$1K
  • Amgen$681
  • AstraZeneca$614
  • Boehringer Ingelheim$612
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$11,85199%
  • Education$1041%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,956 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$70,824
Medicare patients
156
Services billed
1,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$224,527
JardianceEmpagliflozin164$211,053
EliquisApixaban143$124,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter120$121,110
MounjaroTirzepatide66$100,564
TrulicityDulaglutide41$55,511
XareltoRivaroxaban53$50,038
MyrbetriqMirabegron78$48,472
JanuviaSitagliptin Phosphate34$42,188
Synjardy XrEmpagliflozin/Metformin Hcl23$17,587
Mirabegron ErMirabegron32$16,674
FarxigaDapagliflozin Propanediol13$14,888
LinzessLinaclotide23$14,404
Tresiba Flextouch U-100Insulin Degludec16$14,167
TradjentaLinagliptin26$12,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$612$241,288213 claims
Novo NordiskOzempic$1,828$224,527152 claims
Lilly USA, LLCMounjaro, Trulicity$583$156,075107 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,350$144,622164 claims
PfizerEliquis$454$124,399143 claims
Johnson & JohnsonXarelto$355$50,03853 claims
MerckJanuvia, Janumet$291$48,49947 claims
Astellas Pharma US IncMyrbetriq$344$48,47278 claims
AbbVieLinzess, Synthroid$1,910$22,658137 claims
AstraZenecaFarxiga$614$14,88813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Aliquippa

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →